What factors will most influence your decision to offer ENCELTO to patients with macular telangiectasia type 2?  

Yet another (presumably very expensive) surgical treatment for a chronic macular disease was approved on the basis of OCT measurements without demonstrating visual benefit to the patient in a disease with a slow, variable course. Show me quality of life studies and visual benefit justifying surgica...